Dawson v. Merck & Company, Inc.

CourtDistrict Court, E.D. New York
DecidedJanuary 24, 2021
Docket1:12-cv-01876
StatusUnknown

This text of Dawson v. Merck & Company, Inc. (Dawson v. Merck & Company, Inc.) is published on Counsel Stack Legal Research, covering District Court, E.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Dawson v. Merck & Company, Inc., (E.D.N.Y. 2021).

Opinion

UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK -------------------------------------------------------------- x PAUL DAWSON, : : ORDER ON MOTION TO UNSEAL Plaintiff, : : 1:12-CV-1876 (BMC)(PK) -against- : : MERCK & CO., INC. and MERCK SHARP & : DOHME CORP., : : Defendants. x --------------------------------------------------------------

Peggy Kuo, United States Magistrate Judge: Intervenor Reuters America LLC (“Reuters”) moves this Court seeking an order unsealing certain documents filed by the parties in this case. (“Motion,” Dkt. 121.) Defendants Merck & Co., Inc. and Merck Sharp & Dohme Corp. (together “Defendants” or “Merck”) and Plaintiff Paul Dawson opposed the Motion. For the reasons stated herein, the Motion is GRANTED. BACKGROUND On August 18, 2011, Plaintiff filed a complaint against Defendants in the Western District of Washington, alleging that the prescription drug Propecia, manufactured and marketed by Defendants to treat male pattern baldness, caused injury to Plaintiff, including sexual dysfunction. (Dkt. 1 ¶¶ 9, 45, 47.) In 2012, Plaintiff’s complaint was consolidated into a multi-district litigation and transferred to the Eastern District of New York. (Dkt. 11.) In 2016, Plaintiff’s case was selected as one of four “bellwether” cases to represent the first tranche of plaintiffs. (In Re Propecia Finasteride Product Liability Litigation, 12-md-2331 (BMC)(PK) Dkt. 350.) On November 21, 2017, in anticipation of dispositive motions and Daubert motions, the parties sought leave to file documents under seal. (Dkt. 108.) The parties argued that good cause for sealing existed because the anticipated submissions “contain[] confidential information that is subject to the Stipulation and Order Regarding Confidential Information.” Id. The request was granted, and the parties were directed to “file the exhibits under seal in the first instance, and, in the final paragraph of the motion to which the sealed exhibits are attached, the filing party must explain why the exhibits should remain under seal.” (Dkt. Order dated Nov. 21, 2017.) On November 27, 2017, Defendants filed a Motion for Summary Judgment (Dkt. 110) and a Motion to Preclude Plaintiff’s Experts (“Daubert Motion,” Dkt. 111), which Defendants “adopt[ed]

and incorporate[d] by reference” into their Motion for Summary Judgment. (See Dkt. 110-7 at 1 n.1, 10.) On December 27, 2017, Plaintiff filed an Opposition to the Motion for Summary Judgment (Dkt. 114) and an Opposition to the Daubert Motion (Dkts. 113 and 115), which Plaintiff incorporated into his Opposition to the Motion for Summary Judgment. (See Dkt. 114 at 5.) Plaintiff’s Opposition to the Daubert Motion was filed in redacted form at Dkt. 113 and full unredacted form, under seal, at Dkt. 115. Dkt. 113 attached 46 unsealed exhibits, while Dkt. 115 attached 29 sealed exhibits. References in Dkt. 115 to sealed exhibits are redacted from the publicly visible filing at Dkt. 113 using computer-generated redactions. (See generally Dkts. 113, 115.) Nevertheless, Reuters has stated that it was able to read the entirety of Plaintiff’s briefing filed at Dkt. 113, including the content obscured by the redactions, by copying the redacted text from the PDF version available on the Court’s electronic case filing website and pasting the text into Microsoft Word. (See Dkt. 121-1 at 4.)

Before a ruling was made on either the Daubert Motion or the Motion for Summary Judgment, the parties informed the Court of a settlement agreement, and the case was dismissed. (See Order dated Sept. 7, 2018.) The parties thereafter filed a Stipulation of Dismissal on December 17, 2018. (Dkt. 118.) On September 12, 2019, Reuters moved to intervene and to unseal certain documents, specifically to remove the redactions in Plaintiff’s Opposition to the Daubert Motion at Dkt. 113 and to unseal the sealed exhibits at Dkt. 115. (See “Memorandum of Law in Support of Proposed Intervenor Reuters’ Motion to Intervene and Unseal,” Dkt. 121-1.) Plaintiff and Defendants opposed the Motion. (Dkts. 122, 123.) Reuters was granted leave to intervene. (See Order dated Feb. 6, 2020.) After Reuters clarified that it was not seeking to unseal Plaintiff’s confidential medical records1 (see “Reuters’s Reply Memo,” Dkt. 124; Oral Argument Tr. at 14:5-11, 23:10-22, Dkt. 135), Plaintiff

took no further position on the Motion. Accordingly, only Defendants currently oppose the Motion. Oral argument was held on April 15, 2020, at the end of which Defendants were ordered to submit supplemental briefs stating specific reasons each sealed document should remain sealed. (See Minute Entry dated April 15, 2020.) Defendants submitted a supplemental brief in which they withdrew their opposition to certain documents being unsealed (Dkt. 138-3 at 7), and those documents were unsealed. (See Order Dated Sept. 24, 2020.) However, Defendants continued to oppose the unsealing of at least some portions of eleven exhibits, claiming that they contain confidential business information that merited continued sealing. (See Defs.’ Revised Supp. Brief at 6, Dkt. 138-3.) This Order thus considers Reuters’s request to (1) remove the redactions from Dkt. 113, and (2) unseal the eleven exhibits filed at Dkts. 115-5, 115-6, 115-7, 115-10, 115-11, 115-12, 115-18, 115- 21, 115-23, 115-25, and 115-28 (the “Documents”). (Dkt. 121-1 at 6.)

DISCUSSION The public, including the press, has both a common law and qualified First Amendment right of access to certain court proceedings and filings. See Lugosch v. Pyramid Co. of Onondaga, 435 F.3d 110,

1 Defendants represented that Dkts. 115-29 and 115-30 “are Plaintiff’s medical records.” (Dkt. 140 at 1.) On that basis, Reuters does not seek to unseal Dkts. 115-29 or 115-30. As discussed below, however, these documents are not Plaintiff’s medical records, but the medical records of a plaintiff in another of the bellwether cases. 119-20 (2d Cir. 2006). The Second Circuit has prescribed a three-part test to determine whether the common law right of access applies to court documents. First, the documents must be “judicial documents.” See id. at 119. If they are judicial documents, there is a presumption of access to them, and the court must determine the weight of the presumption. Id. The court must then balance that presumption against any reasons for keeping the documents under seal. See United States v. Amodeo, 71 F.3d 1044, 1050 (2d

Cir. 1995) (“Amodeo II”). The more stringent First Amendment analysis is “somewhat different.” Bernstein v. Bernstein Litowitz Berger & Grossmann LLP, 814 F.3d 132, 141 (2d Cir. 2016). There is a presumptive, qualified First Amendment right of access to documents under either the “experience and logic” test or the “necessary corollary” test. Lugosch, 435 F.3d at 120. The experience and logic test “asks both whether the documents have historically been open to the press and general public and whether public access plays a significant positive role in the functioning of the particular process in question.” Newsday LLC v. Cty. of Nassau, 730 F.3d 156, 164 (2d Cir. 2013) (quoting Lugosch, 435 F.3d at 120) (internal quotations omitted). The necessary corollary test applies “only when analyzing judicial documents related to judicial proceedings covered by the First Amendment right [and] asks whether the documents at issue are derived from or are a necessary corollary of the capacity to attend the relevant proceedings.” Newsday LLC, 730 F.3d at 164 (quoting Lugosch, 435 F.3d at 120) (internal quotations omitted)

(alteration added).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Daubert v. Merrell Dow Pharmaceuticals, Inc.
509 U.S. 579 (Supreme Court, 1993)
In Re New York Times Company
828 F.2d 110 (Second Circuit, 1987)
United States v. Amodeo
71 F.3d 1044 (Second Circuit, 1995)
Hartford Courant Co. v. Pellegrino
380 F.3d 83 (Second Circuit, 2004)
Lugosch v. Pyramid Co. of Onondaga
435 F.3d 110 (Second Circuit, 2006)
Stern v. Cosby
529 F. Supp. 2d 417 (S.D. New York, 2007)
Brown v. Maxwell Dershowitz v. Giuffre
929 F.3d 41 (Second Circuit, 2019)
United States v. Amodeo
44 F.3d 141 (Second Circuit, 1995)
Louis Vuitton Malletier S.A. v. Sunny Merchandise Corp.
97 F. Supp. 3d 485 (S.D. New York, 2015)
Steele v. City of Burlington
334 F. Supp. 3d 972 (S.D. Iowa, 2018)
Newsday LLC v. County of Nassau
730 F.3d 156 (Second Circuit, 2013)
United States v. HSBC Bank USA, N.A.
863 F.3d 125 (Second Circuit, 2017)
In re Parmalat Securities Litigation
258 F.R.D. 236 (S.D. New York, 2009)

Cite This Page — Counsel Stack

Bluebook (online)
Dawson v. Merck & Company, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/dawson-v-merck-company-inc-nyed-2021.